After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Recently, Yahoo Finance discussed the stock, revealing that Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Avenue Therapeutics Inc is $5.92M. A total of 2.95 million shares were traded on the day, compared to an average of 5.25M shares.
Insider Activity
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, ATXI has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 3 BUYs and 0 SELLs from insiders. Insiders purchased 819,504 shares during that period but sold 0.
In the most recent transaction, Davidow Robert L sold 353,000 shares of ATXI for 0.14 per share on Dec 11. After the transaction, the 10% Owner now owns 22,000 company shares. In a previous transaction on Dec 11, Davidow Robert L sold 264,000 shares at 0.14 per share. ATXI shares that 10% Owner owns now total 681,000.
Among the insiders who bought shares, Fortress Biotech, Inc. acquired of 418,410 shares on Sep 08 at a per-share price of $0.72. This resulted in the 10% Owner holding 1,032,390 shares of ATXI after the transaction. In another insider transaction, ROSENWALD LINDSAY A MD bought 348,675 shares at $0.72 per share on Sep 08. Company shares held by the Director now total 354,318.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, ATXI has a high of $1.36 and a low of $0.11.
As of this writing, ATXI has an earnings estimate of -$0.1 per share for the current quarter. EPS was calculated based on a consensus of 2 estimates, with a high estimate of -$0.09 per share and a lower estimate of -$0.11. The company reported an EPS of -$0.52 in the last quarter, which was -79.30% lower than expectations of -$0.29.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ATXI’s latest balance sheet shows that the firm has $3.76M in Cash & Short Term Investments as of fiscal 2021. Its Book Value Per Share was -$0.41, while its Total Shareholder’s Equity was $3.45M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ATXI is Buy with a score of 5.00.
